VZV Immunochromatographic Device Using Specific Glycoprotein E Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Varicella-Zoster Virus (VZV) are not rapid or specific, leading to delayed diagnosis and potential severe conditions in immunocompromised individuals.
Innovation Solution
An immunochromatographic analysis device utilizing antibodies that recognize specific regions of the VZV glycoprotein E (VZVgE) to specifically detect VZV without cross-reactivity with other α-herpesviruses, using a combination of gold nanoparticles and a chromatographic medium with antibodies bound to specific amino acid sequences of VZVgE.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then detection capability is provided, but detection speed and specificity are insufficient
Solution Approach 1:
The patent changes the detection parameter by targeting a specific epitope (amino acid sequence at positions 108-135) of VZV glycoprotein E, which is highly specific to VZV and does not cross-react with other herpesviruses. This specific parameter targeting enables both rapid and accurate detection.
Solution Approach 2:
The patent replaces complex mechanical or multi-step detection systems with a simplified lateral flow immunochromatographic assay that uses antibody-antigen binding principles to achieve rapid detection without requiring complex instrumentation or multiple processing steps.
2Measurement precision
If antibodies recognizing VZV glycoprotein E are used, then detection specificity is improved, but cross-reactivity with other α-herpesviruses may occur
Solution Approach 1:
The patent applies local quality by targeting a specific local region (amino acid sequence at positions 108-135) of the VZV glycoprotein E that is unique to VZV and does not exist in other α-herpesviruses. This localized epitope targeting eliminates cross-reactivity while maintaining high specificity.
3Productivity
If rapid detection is achieved, then diagnosis speed is improved, but detection reliability may be compromised
Solution Approach 1:
The patent uses an intermediary approach by employing a specific antibody (recognizing amino acid sequence 108-135 of VZVgE) as a mediator that rapidly binds to VZV glycoprotein E with high affinity and specificity, enabling both fast and reliable detection through a single-step immunochromatographic process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and reliable detection of VZV, improving diagnostic accuracy and speed for varicella or zoster infections.
Implementation Method 1
at least one of the labeling substance retaining part and the detection part contains an antibody which recognizes the amino acid sequence at positions 1 to 188 of glycoprotein E of the Varicella-Zoster Virus
Implementation Method 2
a labeling substance contained in the labeling substance retaining part is a gold nanoparticle
Data Source
Figure 1
AI summary
An object of the present invention is to provide a method for specifically detecting Varicella-Zoster Virus (VZV). The present invention relates to an immunochromatographic analysis device which is an immunochromatographic analysis device for detecting Varicella-Zoster Virus (VZV) including a sample addition part, a labeling substance retaining part, a chromatographic medium part having a detection part, and an absorption part, wherein at least one of the labeling substance retaining part and the detection part contains an antibody which recognizes the amino acid sequence at positions 1 to 188 of glycoprotein E of the Varicella-Zoster Virus (VZVgE) composed of the amino acid sequence of SEQ ID NO: 1.